CHANGE MY LOCATION
Business News
New England braces for Hanna's drenching rains- Southern New England is bracing for drenching rain and gusts near 50 mph as Tropical Storm Hanna runs up the Eastern Seaboard.
Powerful storm raises fears from Caribbean to Gulf- "Extremely dangerous" Hurricane Ike grew to fierce Category 4 strength Saturday as it roared on an uncertain path that forced millions from the Caribbean to Florida, and Louisiana to Mexico, to nervously wonder where it would eventually strike.
Candidates weigh in on stabilizing Fannie, Freddie- The historic takeover of Fannie Mae and Freddie Mac, which could come as soon as Sunday, moved to the forefront of the presidential campaign Saturday as candidates and congressional leaders seized on the enormous implications for taxpayers and the economy.
- The banners, buttons and signs say McCain-Palin, but the crowds say something else.
US holds off on civilian nuclear pact with Russia- Now is not the right time for the U.S. to move forward on a once-celebrated deal for civilian nuclear cooperation with Russia, Secretary of State Condoleezza Rice said Saturday.
- Five days a week, Linda Graham trolls tattered neighborhoods of this once thriving steel city outside Pittsburgh for unregistered voters she can sign up as Democrats - one of thousands of unknown volunteers whose work outside the limelight has already altered the basic arithmetic of the November election.
High-resolution satellite launched in California- A super-sharp Earth-imaging satellite that can detail an area the size of a baseball diamond's home plate from space has been launched into orbit from Vandenberg Air Force Base on the Central California coast.
London calling at New York Fashion Week- Designers at New York Fashion week heard London calling - from 1975.
BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
Brisbane, Calif.
(Map)
-
Prior to Nektar,
"Hoyoung is ideally suited to lead BiPar through this period of expansion
and change, with a robust Phase 2 program underway with BSI-201, a potential
best-in-class cancer therapy," said G.
BiPar is developing multiple compounds designed to inhibit PARP-1 (poly-ADP-ribose polymerase), an enzyme crucial to DNA repair that is upregulated in certain tumors. The company's lead compound, BSI-201, has entered a series of Phase 2 trials in tumors types where PARP is overexpressed. The first of those trials will evaluate BSI-201 in patients with "triple negative" breast cancer, and BiPar expects to begin trials in brain and uterine cancers later this quarter.
"BiPar has an extraordinary platform of product candidates, a robust
biomarker-driven clinical development plan for its lead program, BSI-201, and
an industry-leading management team and board of directors," said
About BiPar Sciences
BiPar Sciences, Inc. (http://www.biparsciences.com) is a clinical-stage biopharmaceutical company developing and commercializing a novel class of tumor-selective drugs designed to meet the significant unmet needs of cancer patients.
|
|
